All lobbying filings

TIBER CREEK GROUP

Lobbying for ASTELLAS PHARMA US, INC. · Pharmacuetical company.

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · District of Columbia · House · Senate · $60,000.00 income · posted Oct 20, 2025

Official filing document

Bills named in this filing 2

HR 946
ORPHAN Cures Act
S 1862
ORPHAN Cures Act

Lobbying activity 2

Health Issues

Issues related to the implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to women's health; Issues related to oncology; Issues related to ophthalmology; Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to the One Big Beautiful Bill Act (PL 119-21).

Medicare/Medicaid

Issues related to the implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the One Big Beautiful Bill Act (PL 119-21).

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.